WASHINGTON — Medicaid must cover drugs that the Food and Drug Administration has approved with a lower standard of evidence through its “accelerated approval” program, the Centers for Medicare and Medicaid Services said Wednesday in a letter to states.

This announcement comes at a time when state Medicaid agencies and private insurers are trying to figure out what to do about high-priced drugs with unclear benefits. One example is Exondys 51, Sarepta’s treatment for Duchenne muscular dystrophy, which can cost $300,000 a year. Some patients have struggled to get this drug covered by Medicaid, even though Medicaid is supposed to cover all FDA approved outpatient drugs after the state program signs a pricing agreement with the company.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy